Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs Buys 17,000 Shares

Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs acquired 17,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was bought at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the transaction, the chief executive officer now owns 559,717 shares in the company, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Lifecore Biomedical Price Performance

Shares of LFCR stock traded down $0.11 on Wednesday, reaching $5.80. 374,903 shares of the company were exchanged, compared to its average volume of 656,841. The business has a 50-day moving average price of $7.05 and a 200 day moving average price of $5.82. Lifecore Biomedical, Inc. has a 1 year low of $3.68 and a 1 year high of $8.90. The company has a market cap of $213.60 million, a price-to-earnings ratio of 72.50 and a beta of 0.98. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. Equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lifecore Biomedical

Institutional investors have recently added to or reduced their stakes in the stock. Legion Partners Asset Management LLC increased its stake in shares of Lifecore Biomedical by 0.6% in the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock worth $15,228,000 after acquiring an additional 18,182 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock valued at $2,948,000 after purchasing an additional 55,703 shares during the last quarter. State Street Corp grew its stake in shares of Lifecore Biomedical by 10.2% in the 3rd quarter. State Street Corp now owns 334,360 shares of the company’s stock valued at $1,648,000 after buying an additional 30,916 shares during the period. Marshall Wace LLP increased its holdings in shares of Lifecore Biomedical by 87.3% during the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after buying an additional 139,887 shares during the last quarter. Finally, DCF Advisers LLC raised its position in shares of Lifecore Biomedical by 2.1% during the 2nd quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock valued at $1,491,000 after buying an additional 6,000 shares during the period. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LFCR shares. Stephens reissued an “equal weight” rating and set a $6.00 price target on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum increased their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 22nd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.